Vedanta Biosciences team at FC Barcelona game during #ECCMID2024 !

There is only one thing harder to get from an investor than💰: candid feedback

I wrote some thoughts here Timmerman Report 🧵 including rationalizations investors give themselves to avoid giving it & how entrepreneurs can improve odds of getting it /1

timmermanreport.com/2024/01/one-th…

8 years (!) before diagnosis, elevated platelets are a signal of developing Crohn’s disease. Great work from Marie Vibeke Vestergaard Tine Jess PREDICT IBD
Cell Reports Medicine cell.com/cell-reports-m…

Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023 - businesswire.com/news/home/2023…

Either VE202 or PBO is added to background therapy. All study participants will have an opportunity to receive VE202. 1o endpoints are safety and endoscopic response; 2o endpoints are clinical response and remission, among others

COLLECTiVE202 collective202study.com is a double-blind, placebo-controlled, randomized clinical trial that is being conducted at sites in the US and EU. It is enrolling 100 patients with mild-to-moderate UC between the ages of 18 and 75 years.

In a Phase 1 study in NHV, VE202 strains colonized robustly, in both a dose- and duration-dependent manner and accelerated conversion of 1o bile acids to immunomodulating 2o bile acids that protect against intestinal inflammation compared to PBO. VE202 was also well tolerated

Results describing the biology and candidate selection of VE202 were previously published in Nature nature.com/articles/natur…
nature.com/articles/natur…
and Amanda Prince will be presenting additional data at the Keystone Symposia “Mechanisms of Microbiota-Immune Interactions”

VE202 is an orally administered, investigational live biotherapeutic product consortium consisting of 16 strains of bacteria, rationally selected to induce immune tolerance in the gut, reverse gut microbiota abnormalities common in IBD, and strengthen the epithelial barrier.

Vedanta has dosed the first patient in a Phase 2 Clinical trial of VE202 for the treatment of ulcerative colitis and received Fast Track Designation for this program

businesswire.com/news/home/2023…

Working with a great team to organize Keystone Symposia Regulation of #BarrierImmunity , this October! Join us to explore emerging #InnateImmunity #Microbiome #SkinImmunity #MucosalImmunity research in Banff! keysym.us/KSBarrierReg24 #KSBarrierReg24

How do you align the cultural & strategic elements of a #biotech financing deal? Tune in to hear K2HV CEO & Founding Managing Director Parag Shah and Bernat Olle 🇺🇦, CEO of portfolio company Vedanta Biosciences, on the #BusinessofBiotech podcast: bit.ly/42NPEqx Matthew Pillar

In this episode of the Business of Biotech, Parag Shah and I discuss with ⁦Matthew Pillar⁩ ins and outs of the fundraising process and how we came to work together, starting with ⁦Luke Timmerman⁩’s Presidential Traverse linkedin.com/posts/matthewp…

The Vedanta Biosciences team ran the JP Morgan Corporate Challenge once again, with standout performances across the board.

We don't use 5k times as a hiring criteria but look 🤷‍♂️

👥 #MISTRAL relies on the participation of more than 50 excellent professionals in the field of research and management.

🧐 All these professionals will be working together for more than 5 years to answer the following questions.

🧵👇

Rajita Menon Rajita Menon did an excellent job presenting Vedanta Biosciences’s work on dose-exposure and exposure-response relationships in the Phase 2 CONSORTIUM study of VE303 for prevention of rCDI #DDW2023

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
vedantabio.com/news-media/pre…

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

vedantabio.com/news-media/pre…

Excited for Rajita Menon share the latest PK/PD data from Vedanta Biosciences VE303 ph2 CDI study at #DDW2023 this morning. A defined consortium can effectively prevent recurrence!

Thank you Nasdaq for giving Vedanta Biosciences the spotlight in Times Square!